2022 World Conference on Lung Cancer (ePosters)-EP14.01-008. Checkpoint Inhibitors Prevent New Onset of Brain Metastases in Relapsed Extensive Disease Small-Cell Lung Cancer

EP14.01-008. Checkpoint Inhibitors Prevent New Onset of Brain Metastases in Relapsed Extensive Disease Small-Cell Lung Cancer

Back to course

Pdf Summary

This research poster presentation discusses a study on the effectiveness of checkpoint inhibitors (CPI) in preventing the development of brain metastases in patients with relapsed small-cell lung cancer (SCLC). The study was conducted using a retrospective multicenter cohort from 2010 to 2020. The primary analysis used a Cox regression model to calculate the hazard ratio for 1-year mortality, and secondary outcomes included intracranial time to progression. Propensity score analyses were also used to address potential confounding factors.<br /><br />The results of the study showed that in patients with relapsed SCLC, CPI treatment was associated with improved survival compared to chemotherapy alone. Furthermore, CPI treatment was found to prolong the occurrence and time to progression of brain metastases compared to conventional chemotherapy. However, this effect was only observed in patients without previously irradiated brain metastases.<br /><br />The study concludes that CPI treatment can prevent the development of new brain metastases in relapsed SCLC patients, particularly in those without irradiated brain metastases. The findings suggest that CPIs may have a therapeutic benefit in SCLC patients with brain metastases. However, further research is needed to validate these findings and investigate the mechanism of action.<br /><br />Overall, this study provides valuable insights into the potential use of CPIs in preventing brain metastases in relapsed SCLC patients. The findings have implications for the treatment and management of SCLC, highlighting the importance of considering CPIs as a therapeutic option for these patients.

Asset Subtitle

Jan Alexander Stratmann

Meta Tag

Speaker Jan Alexander Stratmann

Topic Small Cell Lung Cancer and Neuro-endocrine Tumours - Informing ES-SCLC

Keywords

checkpoint inhibitors

CPI

brain metastases

relapsed small-cell lung cancer

SCLC

retrospective multicenter cohort

hazard ratio

1-year mortality

intracranial time to progression

propensity score analyses